Company Description
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States.
Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.
The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology.
Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Country | MA |
Founded | 2013 |
Industry | Health Information Services |
Sector | Healthcare |
Employees | 200 |
Contact Details
Address: 200 State Street, 13th Floor Boston, Massachusetts 02109 United States | |
Phone | 6469322774 |
Stock Details
Ticker Symbol | PEARQ |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001835567 |
Employer ID | 85-4103092 |
SIC Code | 8000 |
Key Executives
Name | Position |
---|---|
Dr. Corey M. McCann M.D., Ph.D. | Founder and Director |
Ellen E. Snow CPA, CGMA | Vice President and Chief Accounting Officer |
Ilya Gluhovsky Ph.D. | Vice President and Chief Technology Officer |
Meara Murphy | Senior Director of Corporate Communications |
Chris Valosky M.B.A. | Vice President of Sales, Commercial Partnership and Marketing |
Martha Carruthers M.B.A. | Vice President of Corporate Development |
Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer and Head of Development |
Erin K. Brenner | Chief Product Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 2, 2023 | 25-NSE | Filing |
Apr 28, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Apr 12, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Apr 10, 2023 | 8-K | Current Report |
Apr 7, 2023 | 8-K | Current Report |
Mar 31, 2023 | 10-K | Annual Report |
Mar 17, 2023 | 8-K | Current Report |
Feb 24, 2023 | 8-K | Current Report |
Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |